Caribou Biosciences CRBU
NASDAQ CRBU
$0.53 -0.01 (-2.13%)
As of: Oct 22, 2026 · 1:14 PM EDT

Caribou Biosciences (CRBU) Non-Current Debt (2020)

Updated

Caribou Biosciences' Non-Current Debt came in at $924,000 for Q4 2020.

Analysis

Caribou Biosciences (CRBU) Non-Current Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,166.97 Bn 1,135.56 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 644.38 Bn 564.24 Bn 17.30 Bn 35.80 Bn
3 AbbVie 501.54 Bn 474.65 Bn 12.70 Bn 62.48 Bn
4 Merck 359.36 Bn 313.74 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 302.13 Bn 266.12 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 267.59 Bn 241.28 Bn 12.86 Bn 23.68 Bn
7 Amgen 241.49 Bn 196.89 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 192.85 Bn 167.05 Bn 6.22 Bn 23.83 Bn
9 Pfizer 171.77 Bn 118.41 Bn 10.94 Bn 60.50 Bn
10 Caribou Biosciences 53.85 Mn -462.69 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2020 924,000.00
API Access

Caribou Biosciences Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=CRBU&period=max&api_key=YOUR_API_KEY